Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins

British Journal of Biomedical Science

Volumn 62, Issue 1, 2005, Pages 40-46

  Clarke, S C ^a,b,c  

^a Scottish Meningococcus P   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Portsmouth City PCT   (United Kingdom)

Author keywords

Anthrax; Bacteria; Botulism; Toxins; Violence

Indexed keywords

ANTHRAX TOXIN; BACTERIAL TOXIN; BOTULINUM TOXIN; CHOLERA TOXIN; CLOSTRIDIUM TOXIN; ENTEROTOXIN; ENTEROTOXIN B; UNCLASSIFIED DRUG;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIUM; BIOLOGICAL WARFARE; BOTULISM; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM PERFRINGENS; ECONOMIC ASPECT; HUMAN; MORBIDITY; MORTALITY; PANIC; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; STAPHYLOCOCCUS AUREUS; VIOLENCE;

ANTHRAX; ANTHRAX BACILLUS; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM PERFRINGENS; STAPHYLOCOCCUS AUREUS;

EID: 16444381146     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2005.11732685     Document Type: Review

References (66)

1. Guan Y, Peiris JS, Zheng B et al. Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome. Lancet 2004; 363(9403): 99-104.
2. Normile D. Infectious diseases. Stopping Asia's avian flu: a worrisome third outbreak. Science 2004; 303(5657): 447.
3. Parry J. WHO confirms avian flu outbreak in Hanoi. BMJ 2004; 328(7432): 123.
4. Spencer RC, Wilcox MH. Agents of biological warfare. Rev Med Microbiol 1993; 4: 138-43.
5. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM, Jr. Biological warfare. A historical perspective. JAMA 1997; 278(5): 412-7.
6. Takahashi H, Keim P, Kaufmann AF et al. Bacillus anthracis incident, Kameido, Tokyo, 1993. Emerg Infect Dis 2004; 10(1): 117-20.
7. Keim P, Smith KL, Keys C, Takahashi H, Kurata T, Kaufmann A. Molecular investigation of the Aum Shinrikyo anthrax release in Kameido, Japan. J Clin Microbiol 2001; 39(12): 4566-7.
8. Torok TJ, Tauxe RV, Wise RP et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 278(5): 389-95.
9. Kolavic SA, Kimura A, Simons SL, Slutsker L, Barth S, Haley CE. An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. JAMA 1997; 278(5): 396-8.
10. Jernigan JA, Stephens DS, Ashford DA et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7(6): 933-44.
11. Clarke SC. Bioterrorism: an overview. Br J Biomed Sci 2002; 59: 232-4.
12. Atlas RM. Bioterrorism: from threat to reality. Annu Rev Microbiol 2002.
13. Lane HC, Fauci AS. Bioterrorism on the home front: a new challenge for American medicine. JAMA 2001; 286(20): 2595-7.
14. Brookmeyer R, Blades N. Prevention of inhalational anthrax in the US outbreak. Science 2002; 295(5561): 1861.
15. Kadlec RP, Zelicoff AP, Vrtis AM. Biological weapons control. Prospects and implications for the future. JAMA 1997; 278(5): 351-6.
16. Ferguson JR. Biological weapons and US law. JAMA 1997; 278(5): 357-60.
17. Morse SA, Kellogg RB, Perry S et al. Detecting biothreat agents: the laboratory response network. ASM News 2003; 69(9): 433-7.
18. Anon. Presidential Decision Directive 39. Responsibilities to detect, defeat, prevent and manage the consequence of WDM terrorism. 1997.
19. Anon. Presidential Decision Directive 62. Combating Terrorism Directive. 1998.
20. Kortepeter MG, Cieslak TJ, Eitzen EM. Bioterrorism. J Environ Health 2001; 63(6): 21-4.
21. Hamburg MA. Bioterrorism: responding to an emerging threat. Trends Biotechnol 2002; 20(7): 296-8.
22. Leggiadro RJ. The threat of biological terrorism: a public health and infection control reality. Infect Control Hosp Epidemiol 2000; 21(1): 53-6.
23. Klietmann WF, Ruoff KL. Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev 2001; 14(2): 364-81.
24. Manchee RJ, Broster MG, Anderson IS, Henstridge RM, Melling J. Decontamination of Bacillus anthracis on Gruinard Island? Nature 1983; 303(5914): 239-40.
25. Willis EA. Landscape with dead sheep: what they did to Gruinard Island. Med Confl Surviv 2002; 18(2): 199-210.
26. Davis LE. Botulism. Curr Treat Options Neurol 2003; 5(1): 23-31.
27. Muensterer OJ. Infant botulism. Pediatr Rev 2000; 21(12): 427.
28. Brook I. Anaerobic infections in children. Adv Pediatr 2000; 47: 395-437.
29. Kessler KR, Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicology 1997; 18(3): 761-70.
30. Singh BR. Intimate details of the most poisonous poison. Nat Struct Biol 2000; 7(8): 617-9.
31. Franz DR, Jahrling PB, Friedlander AM et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278(5): 399-411.
32. Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285(8): 1059-70.
33. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998; 21(6): 701-10.
34. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82(9-10): 955-66.
35. Robinson-Dunn B. The microbiology laboratory's role in response to bioterrorism. Arch Pathol Lab Med 2002; 126(3): 291-4.
36. Varkey P, Poland GA, Cockerill FR, Smith TF, Hagen PT. Confronting bioterrorism: physicians on the front line. Mayo Clin Proc 2002; 77(7): 661-72.
37. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA 1997; 278(5): 433-5.
38. Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000; 61(1): 1-10.
39. Svensson LA, Schad EM, Sundstrom M, Antonsson P, Kalland T, Dohlsten M. Staphylococcal enterotoxins A, D, and E. Structure and function, including mechanism of T-cell superantigenicity. Prep Biochem Biotechnol 1997; 27(2-3): 111-41.
40. Bohach GA. Staphylococcal enterotoxins B and C. Structural requirements for superantigenic and entertoxigenic activities. Prep Biochem Biotechnol 1997; 27(2-3): 79-110.
41. Le Loir Y, Baron F, Gautier M. Staphylococcus aureus and food poisoning. Genet Mol Res 2003; 2(1): 63-76.
42. Hazariwala A, Sanders Q, Hudson CR, Hofacre C, Thayer SG, Maurer JJ. Distribution of staphylococcal enterotoxin genes among Staphylococcus aureus isolates from poultry and humans with invasive staphylococcal disease. Avian Dis 2002; 46(1): 132-6.
43. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2(3): 156-62.
44. Fraser J, Arcus V, Kong P, Baker E, Proft T. Superantigens - powerful modifiers of the immune system. Mol Med Today 2000; 6(3): 125-32.
45. Krakauer T. Immune response to staphylococcal superantigens. Immunol Res 1999; 20(2): 163-73.
46. Makino S, Watarai M, Cheun HI, Shirahata T, Uchida I. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J Infect Dis 2002; 186(2): 227-33.
47. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M, Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett 2002; 531(3): 384-8.
48. Koehler TM. Bacillus anthracis genetics and virulence gene regulation. Curr Top Microbiol Immunol 2002; 271: 143-64.
49. Ciftci E, Ince E, Dogru U. Traditions, anthrax, and children. Pediatr Dermatol 2002; 19(1): 36-8.
50. Oncul O, Ozsoy MF, Gul HC, Kocak N, Cavuslu S, Pahsa A. Cutaneous anthrax in Turkey: a review of 32 cases. Scand J Infect Dis 2002; 34(6): 413-6.
51. Tutrone WD, Scheinfeld NS, Weinberg JM. Cutaneous anthrax: a concise review. Cutis 2002; 69(1): 27-33.
52. Vijaikumar M, Thappa DM, Karthikeyan K. Cutaneous anthrax: an endemic outbreak in south India. J Trop Pediatr 2002; 48(4): 225-6.
53. Tasyaran MA, Deniz O, Ertek M, Cetin K. Anthrax meningitis: case report and review. Scand J Infect Dis 2002; 34(1): 66-7.
54. Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002; 8(7): 649-51.
55. Cullamar EK, Lutwick LI. Inhalational anthrax. Curr Infect Dis Rep 2002; 4(3): 238-43.
56. Brynestad S, Granum PE. Clostridium perfringens and foodborne infections. Int J Food Microbiol 2002; 74(3): 195-202.
57. Present DA, Meislin R, Shaffer B. Gas gangrene. A review. Orthop Rev 1990; 19(4): 333-41.
58. Spencer RC, Lightfoot NF. Preparedness and response to bioterrorism. J Infect 2001; 43(2): 104-10.
59. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and post-attack intervention programs justifiable? Emerg Infect Dis 1997; 3(2): 83-94.
60. Owens SR. Waging war on the economy. The possible threat of a bioterrorist attack against agriculture. EMBO Rep 2002; 3(2): 111-3.
61. Williams JL, Sheesley D. Response to bioterrorism directed against animals. Ann N Y Acad Sci 2000; 916: 117-20.
62. Wilson TM, Gregg DA, King DJ et al. Agroterrorism, biological crimes, and biowarfare targeting animal agriculture. The clinical, pathologic, diagnostic, and epidemiologic features of some important animal diseases. Clin Lab Med 2001; 21(3): 549-91.
63. Derbes VJ. De Mussis and the great plague of 1348. A forgotten episode of bacteriological warfare. JAMA 1966; 196(1): 59-62.
64. Stubbs M. Has the West an Achilles' heel: possibilities of biological weapons. NATO's Fifteen Nations 1962; 196(7): 94-9.
65. Robertson AG, Robertson LJ. From asps to allegations: biological warfare in history. Mil Med 1995; 160(8): 369-73.
66. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci 1992; 666: 21-52.